Modulators of myc, methods of using the same, and methods of identifying agents that modulate myc

Abstract

Disclosed herein are methods of modulation of the viability of a cell. Further disclosed herein are methods of modulating an immune response. Further disclosed herein are methods of identifying agents capable of modulation of the viability of a cell or an immune response. Further disclosed herein are agents and compositions capable of modulation of the viability of a cell or an immune response.

1 - 20 . (canceled) 
     
     
         21 . A method for reversing anergy in one or more anergic lymphocytes in a subject in need thereof, comprising administering a MYC fusion peptide to the subject, wherein the fusion peptide comprises:
 (i) a transporter peptide sequence; and   (ii) a MYC polypeptide sequence.   
     
     
         22 . The method of  claim 21 , wherein the MYC fusion peptide has Formula (I):
 transporter peptide sequence-MYC polypeptide sequence.   
     
     
         23 . The method of  claim 21 , wherein the MYC fusion peptide has Formula (II):
 transporter peptide sequence-X-MYC polypeptide sequence, wherein -X- is a molecule that links the transporter peptide sequence and the MYC polypeptide sequence.   
     
     
         24 . The method of  claim 21 , wherein the MYC fusion peptide has Formula (II):
 transporter peptide sequence-X-MYC polypeptide sequence, wherein X is at least one amino acid.   
     
     
         25 . The method of  claim 21 , wherein the MYC fusion peptide decreases the amount of anergic lymphocytes in the subject. 
     
     
         26 . The method of  claim 21 , wherein the one or more anergic lymphocytes comprises an anergic B cell or an anergic T cell. 
     
     
         27 . The method of  claim 21 , wherein reversing anergy results in an accelerated primary immune response to an antigen, or an accelerated primary immune response in a subject receiving vaccination against an antigen. 
     
     
         28 . The method of  claim 27 , wherein the antigen is from a virus selected from the group consisting of: hepatitis A, hepatitis B, polio; measles; mumps; rubella; diphtheria; pertussis; tetanus; influenza; varicella zoster virus; rotavirus; meningococcal; pneumonia; smallpox; cholera; bubonic plague; yellow fever; tuberculosis; and human papillomavirus. 
     
     
         29 . The method of  claim 21 , where the MYC fusion peptide increases the rate at which a lymphocyte ends anergy. 
     
     
         30 . The method of  claim 21 , wherein reversing anergy results in an increase in the expression of IgM, IgMa, IgMb, B220, CD21/35, CD23, CD24 (HSA), CD40, CD69, CD80 and/or CD86 (B7-2). 
     
     
         31 . The method of  claim 21 , wherein the MYC fusion peptide is formulated for oral administration, parenteral administration, intranasal administration, buccal administration, rectal administration, or intravenous administration. 
     
     
         32 . The method of  claim 21 , wherein the MYC fusion peptide is formulated for intramuscular or subcutaneous administration. 
     
     
         33 . The method of  claim 21 , wherein the MYC fusion peptide is formulated for topical or transdermal administration. 
     
     
         34 . The method of  claim 21 , wherein the MYC fusion peptide is formulated as a delayed release formulation or as an extended release formulation.